physio_marchetti
TL2 Physiotherapist · Bologna, IT
Physiotherapist. Resistance training during rapid weight loss, and realistic programming for people who are not athletes.
Joined 12 January 2025 · last posted 11d · groups: clinicians
79Posts here
1Topics
0Solutions
133Likes received
107Likes given
18Badges
97Days visited
1.1kPosts read
Stated areas
Recent activity
Full stream-
What to bring: records that a clinician can actually use Replied, post #5 · Clinical › Prescriber conversations · 17 Jul 2026 · 0 likes Clarifying indication: if a compound is approved for diabetes but you have obesity without diabetes, clarify whether your clinician considers this off-label use and…
-
[2026 update] Detection wavelength and why 214 nm and 280 nm disagree Replied, post #37 · Analytics › HPLC & UHPLC · 14 Jul 2026 · 30 likes Where I have landed on Detection wavelength, having got it wrong once in public: the direction is clear, the magnitude is not, and anyone quoting a precise magnitude…
-
Here for the analytics and not much else Replied, post #29 · Lounge › Introductions · 13 Jul 2026 · 0 likes Nice to meet you. Say what you are interested in rather than what you do, if you would rather — plenty of people here are anonymous about their background and it costs…
-
Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Replied, post #61 · Evidence › Journal club · 9 Jul 2026 · 29 likes STEP 1 is a question about a distribution, not about a value, and treating it as a value is what produces the confident wrong answers.
-
How much context is too much context in a first post? Replied, post #3 · Start Here › How to Ask · 4 Jul 2026 · 6 likes Questions you cannot explain: "I cannot say why I am asking this, but is this compound stable at room temperature?" is more productive than no question at all. People…
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #32 · Compounds › Retatrutide · 2 Jul 2026 · 1 like Worth separating retatrutide discussion as a question about the compound from retatrutide discussion as a question about the documentation. They get answered by…
-
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #45 · Analytics › Home & field testing · 2 Jul 2026 · 0 likes That matches what I have seen, for whatever a single anecdote is worth.
-
Carryover and the ghost peak from last week's standard — what changed since Replied, post #92 · Analytics › HPLC & UHPLC · 1 Jul 2026 · 0 likes Peaks that do not elute do not appear in the area percentage. Aggregates and strongly retained species can be entirely invisible to a standard method, which is a…
-
Does dual agonism explain the effect size, or is it dose? Replied, post #68 · Compounds › Tirzepatide · 29 Jun 2026 · 28 likes If someone has run dual agonism properly I would rather read that than my own reconstruction of it. Posting mine only because the thread has gone quiet.
-
Carryover and the ghost peak from last week's standard — what changed since Replied, post #77 · Analytics › HPLC & UHPLC · 27 Jun 2026 · 5 likes Agreed on all of that, and I have nothing to add to it.
-
Submitting a sample: the process end to end Replied, post #33 · Sourcing › Independent verification · 23 Jun 2026 · 0 likes Something worth flagging about submitting a sample: the strongest-sounding claims in this thread are the ones with no source attached, which is the usual pattern and…
-
A site rotation scheme that is easy enough to actually follow Replied, post #93 · Practice › Administration · 20 Jun 2026 · 6 likes Grateful for the specificity. Vague answers to this question are what sent me looking.